Executive Chairman at Flen Pharma
Philippe Sollie founded Flen Pharma in 2000, with the aim to contribute to wound healing with better products. The motive was, as so many of us have experienced, a particular event in life: a 1 year old daughter of friends who was severely burnt in a BBQ accident. Following the therapeutic ordeal of his friends’ daughter, he saw that while infection could largely be prevented, scar formation was a major concern, and that allergies to the treatment only added to the suffering of the little girl. In subsequent years, publications pointed out that antimicrobials were inherently cytotoxic, an additional problem especially in poorly healing wounds. In short, Philippe Sollie feels there is much more to wound healing than mainly dealing with infections; this does remain a prime concern, though not the only one. Burns, his initial focus of interest have been widened to include a host of other wounds. Venous ulcers, diabetic foot ulcers, pressure sores, post operative wounds, oncology wounds (e.g. after radiation therapy) and preventing scars after plastic surgery. Philippe Sollie relies on working hand in hand with the professionals who use his company’s products and to whom he acknowledges their vital input in creating the products.
Pharma Research and Business